Arbutus Biopharma CorpABUSEarnings & Financial Report
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Revenue
$4.7M
Gross Profit
N/A
Operating Profit
$-21.6M
Net Profit
$-20.1M
Gross Margin
N/A
Operating Margin
-462.8%
Net Margin
-431.6%
YoY Growth
-21.7%
EPS
$-0.12
Arbutus Biopharma Corp Q3 FY2023 Financial Summary
Arbutus Biopharma Corp reported revenue of $4.7M (down 21.7% YoY) for Q3 FY2023, with a net profit of $-20.1M (down 14.4% YoY) (-431.6% margin).
Key Financial Metrics
| Total Revenue | $4.7M |
|---|---|
| Net Profit | $-20.1M |
| Gross Margin | N/A |
| Operating Margin | -462.8% |
| Report Period | Q3 FY2023 |
Revenue Breakdown
Arbutus Biopharma Corp Q3 FY2023 revenue of $4.7M breaks down across 2 segments, led by Collaboration And Contracts at $3.9M (84.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Collaboration And Contracts | $3.9M | 84.5% |
| Other | $723.0K | 15.5% |
Arbutus Biopharma Corp Revenue by Segment — Quarterly Trend
Arbutus Biopharma Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Collaboration And Contracts and Other) has evolved quarter over quarter.
| Segment | Q2 FY2025 | Q4 FY2023 | Q3 FY2023 | Q2 FY2023 |
|---|---|---|---|---|
| Collaboration And Contracts | — | $945.0K | $3.9M | $3.9M |
| Other | — | $1.2M | $723.0K | $766.0K |
Arbutus Biopharma Corp Annual Revenue by Year
Arbutus Biopharma Corp annual revenue history includes year-by-year totals (for example, 2023 revenue was $18.1M).
| Year | Annual Revenue |
|---|---|
| 2023 | $18.1M |
| 2022 | $39.0M |
Arbutus Biopharma Corp Quarterly Revenue & Net Profit History
Arbutus Biopharma Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $10.7M | +522.2% | $2.5M | 23.5% |
| Q4 FY2023 | $2.1M | -65.7% | N/A | N/A |
| Q3 FY2023 | $4.7M | -21.7% | $-20.1M | -431.6% |
| Q2 FY2023 | $4.7M | -67.3% | $-17.1M | -367.5% |
| Q1 FY2023 | $6.7M | -46.8% | $-16.3M | -244.3% |
| Q4 FY2022 | $6.2M | +94.8% | $-21.9M | -351.2% |
| Q3 FY2022 | $6.0M | +78.2% | $-17.6M | -295.1% |
| Q2 FY2022 | $14.2M | +511.5% | $-14.2M | -99.7% |
Income Statement
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $6.0M | $6.2M | $6.7M | $4.7M | $4.7M | $2.1M | $10.7M |
| YoY Growth | 511.5% | 78.2% | 94.8% | -46.8% | -67.3% | -21.7% | -65.7% | 522.2% |
Balance Sheet
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $215.8M | $203.8M | $195.4M | $191.2M | $176.8M | $158.6M | $144.4M | $103.3M |
| Liabilities | $62.7M | $58.3M | $58.6M | $47.3M | $42.1M | $39.3M | $38.4M | $20.3M |
| Equity | $153.1M | $145.5M | $136.9M | $143.9M | $134.7M | $119.3M | $106.0M | $83.0M |
Cash Flow
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.3M | $-18.7M | $-17.0M | $-27.3M | $-19.6M | $-21.8M | $-17.3M | $-15.7M |